Johnson & Johnson ordered to pay man $8bn over breast growth

Johnson and Johnson logo is seen at an office building in Singapore

A Philadelphia jury has ruled that Johnson & Johnson and Janssen Pharmaceuticals must pay $8 billion in punitive damages over an antipsychotic drug linked to the abnormal growth of female breast tissue in boys.

A sign is posted at the Johnson & Johnson campus on 26 August 2019 in Irvine, California.

A Philadelphia jury has directed United States drug firm Johnson & Johnson to pay $8 billion to a man who claims to have developed breasts by using the drugs manufactured by the company, according to a report in Forbes.

Johnson & Johnson denied the allegations, and said it's confident the ruling will be overturned.

Plaintiffs claim that Johnson & Johnson failed to warn of the risk of gynecomastia (the development of enlarged breasts in males) associated with Risperdal, which they say J&J marketed for unapproved use with children.

Murray said he was prescribed the medicine at age 9 for symptoms related to autism spectrum disorder, despite the fact that the FDA's approval of the drug in the 1990s was to treat schizophrenia and episodes of bipolar mania in adults.


Professor Carl Tobias of the University of Richmond School of Law said he expects the punitive damages to be lowered on appeal, citing a U.S. Supreme Court decision which found that "few awards exceeding a single-digit ratio between punitive and compensatory damages, to a significant degree, will satisfy due process". J&J in 2013 agreed to pay $2.2 billion to settle a federal off-label marketing probe over the drug.

"This jury, as have other juries in other litigations, once again imposed punitive damages on a corporation that valued profits over safety and profits over patients".

While the drug can treat certain mental health disorders, Murray's lawyers charged that it also has a tendency to create a hormonal imbalance, with elevated levels of a hormone called prolactin. Aside from thousands of Risperdal lawsuits, the company faces about 15,500 talc cases and opioid litigation from across the country, among other legal issues.

More recently, a judge in Oklahoma ordered the company to pay $572 million after that state sued the drugmaker for its opioid marketing.

Johnson & Johnson was ordered to pay $575m by Oklahoma earlier this year over the company's historic involvement in the opioid crisis and earlier this month it reached a $20.4m settlement in OH over similar cases.

Last week, however, Johnson & Johnson reached a $20.4 million settlement with two OH counties in another massive suit on the opioid crisis.

Related:

Comments

Latest news

Lionel Messi: FC Barcelona talisman admits fears of Neymar transfer to
Messi maintains there are no issues and knows adapting to Barcelona and the current interpretation of their famed style takes time.

A Closer Look at Modern Warfare's Co-op Special Ops Mode
Operations are the larger, multi-stage feature for Special Ops in Modern Warfare and Missions are built within the Operations . The choice will always be yours, but the enemy will respond to your tactics, meaning the outcome of any battle can change.

US Loses Top Spot to Singapore in Competitiveness Rankings
Among the South Asian nations, India is at 68, with Sri Lanka 84 and Bangladesh at 105 and Nepal at 108. Singapore has become the world's most competitive economy in 2019, pushing the USA to the second place.

Essential's upcoming 'Project Gem' smartphone has a very unusual design
Rather than the tweets of Rubin and essential official account, no further information is given about Essential's next phone. They look highly-reflective, and the colour hues appear to change depending on the angle (refer to video above).

This Is How Much The Pixel 4 Series Will Cost… In Canada
Makes the Pixel 4 XL 64GB not look so bad doesn't it? These two handsets have been leaking for quite some time now. But today, we have another leak that specifies pricing of both the Google Pixel 4 and the Google Pixel 4 XL.

Other news